PTGS2 and non-small cell lung carcinoma: To better assess the efficacy of COX-2 inhibitors for NSCLC, we conducted three subgroup analyses according to types of COX-2 inhibitors (celecoxib, rofecoxib, or apricoxib), treatment pattern (with chemotherapy, radiotherapy or TKIs), and treatment line (first or second).